{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059491","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.665129+00:00","generated_at":"2026-06-02T01:03:57.622614+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Korro Bio Q1 net loss $19.6M; appoints Kemi Olugemo as CMO; cash $138.8M plus $70M PIPE","bullets":["Net loss $19.6M in Q1 2024, unchanged from Q1 2023; R&D $13.6M, G&A $7.9M.","Cash $138.8M at Mar 31, 2024; after $70M April PIPE, pro forma ~$206M; runway into H2 2026.","Appointed Kemi Olugemo, MD, as Chief Medical Officer; she brings >10 yrs industry experience.","Regulatory filing for KRRO-110 (RNA editing for AATD) on track for H2 2024; interim data H2 2025.","$70M PIPE led by Deep Track Capital with Atlas Venture, NEA, and other healthcare investors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059491","json":"https://secwatch.observer/filing/0000950170-24-059491.json","markdown":"https://secwatch.observer/filing/0000950170-24-059491.md","text":"https://secwatch.observer/filing/0000950170-24-059491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024059491/0000950170-24-059491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024059491/krro-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:03:57.622614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"805064eecae0f6445447648fa05dd3e09fd75b47","claim":"Korro Bio, Inc. reported first quarter of 2024 results: net income $19.6 million.","evidence_excerpt":"Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024059491/0000950170-24-059491-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Net income","value":"$19.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}